BioMagnetic Solutions' super power is nano-magnetic Ferrofluids. Our automated FerroSelect Array cell selection system is designed for PD and GMP CAR-T cell & gene therapy product manufacture, Our Ferofluids are highly magnetic, nano particles that are dynamic, colloidal, no-mixing needed, magnetic liquids for bio-separations. BioMagnetic Solutions' ferrofluids have ideal properties for cell selection. BioMagnetic Solutions is part of Gamma Biosciences.

BioMagnetic Solutions launched its FerroSelect™ Array cell selection system for CAR-T cell & gene therapy (CGT) product manufacture in 2023. FerroSelect™ provides a true Path to GMP - first in PD/RUO format with fully GMP device & immuno-magnetic FerroSelect Ferrofluid reagents for CGT product manufacture in Q4:23. BioMag's FerroSelect™ cell selection is elegantly simple, very fast & highly flexible. FerroSelect™ is an automated, closed system driven by BioMag's "common capture" universal Ferrofluids and biotinylated mAbs. FerroSelect™ uses 2-step indirect mAb labeling protocols with our universal streptavidin Ferrofluids for CAR-T and CGT product manufacture.Gamma Biosciences is a leading life sciences company providing products to support the development and manufacturing of advanced biologic therapies. Gamma’s operating companies are advancing the science and art of bioprocessing by delivering market-ready innovation and expertise that helps our customers, mainly biopharma companies and CDMOs bring therapies to patients more quickly and efficiently. Gamma is a global company with offices and major manufacturing facilities in North America, the U.K. and Belgium.Called X-GRAFFE™ in engineering beta, the FerroSelect™ Array is BioMag’s fully automated instrument and system for immunomagnetic cell selection for CGT products.see Gamma Biosciences' portfolio of biotechs @ https://www.gammabiosciences.com

Guided BioMagnetic Solutions to closing for our Jan 15, 2021 deal with KKR's Gamma Biosciences team and Troutman Pepper Hamilton's team upon the unexpected death of my legendary and pioneering co-founder, CEO & CSO Paul A. Liberti, PhD whose dynamic Ferrofluid technology & systems we're bringing to market worldwide for clinical cell separation & bioprocessing.

From its Immunicon (NASDAQ: IMMC) FDA-approved CELLSEARCH® immunomagnetic cell selection roots, BioMagnetic Solutions (BioMag) brings 30+ years of magnetic cell selection technology, state-of-the art performance & product development.BioMag is bringing to market its FerroSelect™ Array Clinical-Scale Cell Selection system for cell & gene therapy product manufacture. Having pioneered the development of ferrofluids & path-breaking magnetic separation platforms from our Immunicon lineage [developer of CELLSEARCH® the only FDA-approved circulating tumor cell CTC assay], BioMag's Ferrofluids & magnetic platforms provide cell selection tools and platforms for CGT applications. BioMag's' co-founder, COO/CFO & EVP Business Development responsible for: partnering, marketing & strategy for: cell therapy, cell separation, rare cell/CTC applications & bioprocessing applications with life science, biopharma & biotech partners.Called X-GRAFFE™ in protype, FerroSelect™ Array is BioMag’s fully automated instrument and system for immunomagnetic cell selection for CAR-T cell & cell-based gene therapy products.

Business development, market research, marketing, finance, economic & strategic consulting for BFTP's portfolio of high-tech: life-sciences, IT & software firms. Analyze new technology-based startups's: product development, potential markets & R&D partners, corporate partnering strategies/tactics & next-stage capital needs.

European Business Development, Marketing, strategy & economic analysis projects. Patent valuation of IMMC's immunoassay assets & non-core areas of interest for IMMC asset sales. Strategic projects to guide IMMC's go-to-market options for Immunicon's CEOs. Business development for immunoassay & MRI with bioMérieux SA, Geurbet SA and Sweden's Nycomed Pharmaceutical.Immunicon (NASDAQ: IMMC) developed & commercialized CELLSEARCH, the world's only FDA-approved suite of circulating tumor cell (CTC) assays for monitoring epithelial cell-based cancers: metastatic breast, prostate & CRC cancers. Immunicon’s founder, CEO and chief scientist, Paul A. Liberti, developed Immunicon’s class of biologically-active nanomagnetic particles (ferrofluids) at the heart of CELLSEARCH’s CTC cancer & rare cell diagnostic assays. CELLSEARCH's rare cell isolation technology & downstream molecular-based diagnostics provide key analytical services to pharma & biotech for determining the efficacy of new cancer drug compounds in the clinic.In 2008, Johnson & Johnson’s cancer diagnostics division VERIDEX (now Janssen Diagnostics) acquired Immunicon and its path-breaking CELLSEARCH technology. Janssen Diagnostics markets CELLSEARCH for both cancer disease management & cancer lead development in the clinic, see https://www.cellsearchctc.com/CELLSEARCH's platform identifies, counts and characterizes very small number of rare blood cells, such as CTCs and circulating endothelial cells (CECs). CELLSEARCH's platform has also been applied to CEC isolation for cardiovascular disease prevention & management.In 2009, VERIDEX accepted the very prestigious Prix-GALIEN for Immunicon's path-breaking invention & CELLSEARCH product development for the Best Medical Technology 2009, see http://bit.ly/CellSearchPrixGalien The CellSearch CTC assay suite of products remain the only FDA-approved test for monitoring CTCs.Immunicon raised $85M in its 2004 NASDAQ IPO - see http://bit.ly/Immunicon_IPO_NASDAQ

Co-founder, proof of concept studies of AMS' nanomagnetic industrial waste water remediation technologies for acid-mine drainage & shale gas flowback water applications. As EPA standards rise, AMS' proprietary technology stands ready to extract heavy, industrial and precious metals with major partnering water remediation firms.

Founded, built, marketed & organized PA's 3rd largest PLCB-sponsored wine marketing & education platform with the wine industry for Penn State's Annual International WPSU Wine Festival. In 2010, Pennsylvania's PLCB designated the festival a PLCB-sponsored on-site store event per its May Pittsburgh, Hershey and Philadelphia wine festivals. The Penn State Wine Festival promoted: PLCB Chairman Selections & luxury/listed wines, raising funds for Penn State's PBS/NPR affiliate WPSU.Sole responsibility for curating & selecting the festival's wine selections with world-class importers, distributors, top-tier brokers and west-coast wineries for the festival's PLCB-sponsored on-site store event. Managed our marketing, business development, PR, organizational and wine education efforts to showcase over 300+ wines to a growing upscale wine market demographic eager to learn more about fine wines.2011’s PLCB-sponsored event featured 87+ in-store SKUs and was co-sponsored by Spain's Vibrant Rioja NYC trade group. From 2008 to 2011 - assembled a first-class collection of suppliers, raising $120,000+ from 2009 to 2011 for a lucrative platform for future funding raising successes & paving the way for the festival's international emphasis & branding by the WPSU International Wine Festival.

Co-founded, launched & grew Liberti Pincus Ltd. (LPL) a boutique wine* & spirits import & distribution company with S. Bruce Pincus, General Counsel, Minitab Inc. LPL obtained all the required TTB & PLCB licenses and permits to imports wines from: *France, Italy, Portugal, Spain, South America, CA & Oregon.

Wine marketing consulting to non-U.S. wineries & smaller U.S. wineries introducing their wines to mid-Atlantic markets & PA's PLCB monopoly market to find the ideal distributor, wholesaler and/or retailer match. Extensive experience, knowledge & highly developed wine marketing network of wine marketing industry contacts, wine importers & colleagues from wine festival marketing colleagues from: Inter-Rhône, les Vignerons Indépendants de France (VIF), Sud de France, Bordeaux, Provence, Argentina, CWE, AWS, WSET, VinItaly and vintner/vignernons colleagues.

Doctoral research: entrepreneurship, technology, innovation and strategy. Executive decision-making research with Kevin Steensma, University of Washington's Foster School of Business. Organizational theory, technology and network theory applications with Martin Kilduff, Diageo Professor of Management at Cambridge University's Judge School of Business and Professor of Organizational Behavior at University College of London's Department of Management Science and Innovation (MS&I).

Strategic & economic advisor to Delaware’s Director of Revenue, Secretary of Finance, Governor and key financial stewards re: best strategic actions after the passage of the 1994 Reagle Neal National Banking Act that replaced state-level taxation with Federal/national bank taxation. Fascinating strategic, tax & economic analysis with: DE Director of Revenue William Remington, CMU's Prof. Robert Strauss & Nathan Hayward III and DE's internal economic forecasting team.

JP Morgan Paris ~ La Banque Morgan14 Place Vendôme Paris, 75001 FRANCE - Equity & Corp. Actions teamsExcellent vantage into the French economy & its financial markets with a team of world-class colleagues at a bank known for excellence in: investment banking, private banking, capital markets via JPM's deep commercial ties to French, European and American markets & firms. Various roles with J.P. Morgan Paris'​ equity team & agents [in French] while interfacing with J.P. Morgan's London & New York institutional clients. "First-class business in a first-class way."

Trained with Watford Football Club's youth team under FA-Cup winning coach Tom Walley (Watford captain & ex-Welsh international). Arguably the UK's hardest trained team, Watford FC provided life-long lessons in hard work, leadership, teamwork, dedication, strategy and resilience. Watford FC's successes provided excellent lessons in David vs. Goliath strategy, planning & game-day execution.Under Sir Elton John's ownership, Watford FC's 86-87 1st team reached one of the club's apex moments under Sir Graham Taylor's coaching leadership, Sir John Barnes' brilliant play & Watford's team vs. individual ethos propelled the team to a world-class 1st Division/Premiereship 1986-87 season.